Cargando…
The treatment of polycythaemia vera: an update in the JAK2 era
The clinical course of polycythaemia vera is marked by a high incidence of thrombotic complications, which represent the main cause of morbidity and mortality. Major predictors of vascular events are increasing age and previous thrombosis. Myelosuppressive drugs can reduce the rate of thrombosis, bu...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780604/ https://www.ncbi.nlm.nih.gov/pubmed/17551678 http://dx.doi.org/10.1007/s11739-007-0003-4 |